Drugmakers, biotech VCs renew focus on osteoporosis after regulatory shift

Pharma and biotech investors are re-engaging with osteoporosis drug development, driven by a long-awaited regulatory change that improves the commercial outlook. The shift signals a potential pipeline revival in a historically underfunded therapeutic area. The specific regulatory change and its scope are not detailed, leaving the magnitude of the impact uncertain.